External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Krishna Institute of Medical Sciences / Equity Bottom-Up

<div><div><div><div><ul><li>The company’s occupancy rate reduced to 71% vs 84.8% matured assets are delivering continuous lower occupancies as company is losing market share from competitors. ARPOB is stable Rs 26,341, led by speciality surgeries into the lungs and heart segment.</li></ul><div><div><div><div><ul><li>The business has almost reached the pre-Covid levels with In-Patient (IP) volumes increasing by 10% on a YoY basis.</li><li>The newly added therapies such as heart and lung transplants, advanced gastroenterology and liver transplant have seen robust growth this financial year and we are confident that these advanced therapies will help offer better clinical care to more people in the coming years.</li></ul></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The company’s occupancy rate reduced to 71% vs 84.8% matured assets are delivering continuous lower occupancies as company is losing market share from competitors. ARPOB is stable Rs 26,341, led by speciality surgeries into the lungs and heart segment.The business has almost reached the pre-Covid levels with In-Patient (IP) volumes increasing by 10% on a YoY basis.The newly added therapies such as heart and lung transplants, advanced gastroenterology and liver transplant have seen robust growth this financial year and we are confident that these advanced therapies will help offer better clinical care to more people in the coming years.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences LTD - Challenge to Drive Topline Growth

Global Healthcare Analyst

Tina Banerjee

Apollo Hospitals Enterprise / Equity Bottom-Up

<ul>
<li>Medical tourism in India was negatively impacted by the pandemic. As the government is lifting travel restrictions, reopening border, and resuming international flight services, medical tourists have started returning back.</li>
<li>Large corporate hospitals, having pan-India presence, like <a href="https://www.smartkarma.com/entities/apollo-hospitals-enterprise" target="_blank" data-smartkarma-citation="entities:880:1" rel="noopener">Apollo Hospitals Enterprise (APHS IN)</a> are set to benefit from this trend. Medical tourism contributed 10% of revenue of Apollo in pre-pandemic era.</li>
<li>Apollo’s market dominance and expansion plan in hospital and foray into online services have sharpened its competitive edge over competitors. Its healthcare business is expected to grow mid-teens this year.</li>
</ul>


Medical tourism in India was negatively impacted by the pandemic. As the government is lifting travel restrictions, reopening border, and resuming international flight services, medical tourists have started returning back.
Large corporate hospitals, having pan-India presence, like Apollo Hospitals Enterprise (APHS IN) are set to benefit from this trend. Medical tourism contributed 10% of revenue of Apollo in pre-pandemic era.
Apollo’s market dominance and expansion plan in hospital and foray into online services have sharpened its competitive edge over competitors. Its healthcare business is expected to grow mid-teens this year.


Apollo Hospitals Enterprise (APHS IN): Set to Benefit from Medical Tourism Resumption in India

<div><div><div><div><ul><li>The company’s occupancy rate reduced to 590bps YOY due to COVID 3.0 in Jan’22 but it has since picked up momentum.</li></ul><div><div><div><div><ul><li>ARPOB improved to Rs 25,144., led by speciality surgeries into the lungs and heart segment.</li></ul><div><div><div><div><ul><li>The business has almost reached the pre-Covid levels with In-Patient (IP) volumes increasing by 25% on a YoY basis.</li></ul></div></div></div></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The company’s occupancy rate reduced to 590bps YOY due to COVID 3.0 in Jan’22 but it has since picked up momentum.ARPOB improved to Rs 25,144., led by speciality surgeries into the lungs and heart segment.The business has almost reached the pre-Covid levels with In-Patient (IP) volumes increasing by 25% on a YoY basis.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Result Update -  Krishna Institute of Medical Sciences LTD

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Rainbow Children's Medicare / Equity Capital Markets

<ul>
<li>Rainbow Children’s Hospital (RCH) raised around US$200m via issuing a mix of primary and secondary shares in its India IPO.</li>
<li>RCH is a multi-specialty pediatric and obstetrics and gynecology hospital chain in India, operating 14 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds.</li>
<li>In this note, we will talk about our the trading updates.</li>
</ul>


Rainbow Children’s Hospital (RCH) raised around US$200m via issuing a mix of primary and secondary shares in its India IPO.
RCH is a multi-specialty pediatric and obstetrics and gynecology hospital chain in India, operating 14 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds.
In this note, we will talk about our the trading updates.


Rainbow Children’s Hospital IPO Trading - Decent Anchor, Strong Insti Subs but Limited Upside

<ul>
<li>Rainbow Children’s Hospital (RCH) aims to raise around US$200m via issuing a mix of primary and secondary shares in its India IPO.</li>
<li>RCH is a multi-specialty pediatric and obstetrics and gynecology hospital chain in India, operating 14 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds.</li>
<li>In this note, we will talk about the recent updates and peer comparison.</li>
</ul>


Rainbow Children’s Hospital (RCH) aims to raise around US$200m via issuing a mix of primary and secondary shares in its India IPO.
RCH is a multi-specialty pediatric and obstetrics and gynecology hospital chain in India, operating 14 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds.
In this note, we will talk about the recent updates and peer comparison.


Rainbow Children’s Hospital - Recent Updates and Peer Comp

India

Krishna Institute of Medical Sciences Limited provides hospital services. The Hospital offers medical and surgical, renal and cardiac sciences, oncology, orthopaedics, organ transplantation, neurosciences, and other health care services. Krishna Institute of Medical Sciences serves patients in India.

Krishna Institute of Medical Sciences (KIMS IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Krishna Institute of Medical Sciences (KIMS IN)

Krishna Institute of Medical Sciences LTD - Challenge to Drive Topline Growth

In Q1FY23, Standalone revenue (ex. Sunshine) Rs 385 Cr increased by 7.4% which is below as compare to industry growth. Group revenue (incl....

Axis Direct

Apollo Hospitals Enterprise (APHS IN): Set to Benefit from Medical Tourism Resumption in India

Apollo, due to its pan India presence and advanced technology offering, is set to benefit from reviving medical tourism in India. Its healthcare...

Tina Banerjee

Result Update - Krishna Institute of Medical Sciences LTD

Krishna Institute of Medical Sciences (KIMS) reported adjusted revenue of Rs 372 Cr in Q4FY22, registering a growth of 3.8% YoY (below our...

Axis Direct

Rainbow Children’s Hospital IPO Trading - Decent Anchor, Strong Insti Subs but Limited Upside

Rainbow Children’s Hospital raised around US$200m in its India IPO. In this note, we look at the subscription levels and talk about the trading...

Sumeet Singh

Rainbow Children’s Hospital - Recent Updates and Peer Comp

Rainbow Children’s Hospital (RCH) aims to raise around US$200m via issuing a mix of primary and secondary shares in its India IPO. In this note, we...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)